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Objectives This study was designed to evaluate whether replacing CD31 (PECAM-1) signaling can restore the regulation of
lymphocyte activation and improve experimental atherosclerosis.
Background Atherosclerosis, the principal cause of myocardial infarction and stroke, is due to the development of a patho-
genic immune response within the vascular wall and is aggravated by the reduction of regulatory T-cells. CD31,
a transmembrane adhesion molecule with inhibitory signaling functions, is physiologically expressed on blood
and vascular resting cells but is lost in pathologic conditions associated with atherosclerosis.
Methods Replacement therapy with a CD31 receptor globulin (Rg) was delivered by in vivo gene transfer in 6-week-old
apolipoprotein E knockout mice (n  14 per group) every 5 weeks for 6 months. Control groups were treated
with a truncated CD31Rg or with vehicle alone. At the end of the study, plaque size and morphology and blood
T-cell compartment were analyzed in all mice.
Results Atherosclerotic lesions of CD31Rg-treated mice were smaller (p  0.01) and showed less neovascularization
and intraplaque hemorrhage (p  0.05) compared with control subjects. Furthermore, circulating regulatory
T-cells were increased in vivo (p  0.01) and showed normal suppressive function on proliferation of conven-
tional T-cells in vitro. Indeed, CD31Rg treatment led to blunted blood T-cell activation (p  0.05) and reduced
T-cell infiltration within plaques (p  0.01).
Conclusions Our data suggest that CD31 plays a key role in the regulation of the immune response linked to atherosclerosis.
CD31-targeting therapeutic approaches may therefore be envisaged for preventing and treating atherosclerotic
diseases. (J Am Coll Cardiol 2007;50:344–50) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.040t
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mtherosclerosis results from the infiltration of lipoproteins
n the intimal space and the development of a pathogenic
mmune response to modified lipoproteins and other in-
ammatory stimuli within the arterial wall (1). Such re-
ponse develops at the blood–vessel interface between cells
ining the vascular wall (endothelial cells) and cells flowing
ithin the bloodstream such as platelets, lymphocytes,
ranulocytes, and monocytes. Under physiologic conditions,
ctivated blood cells can circulate within the arteries without
ttacking each other or the cells of the arterial wall,
ndicating the presence of a constitutive physiologic control
echanism able to prevent inappropriate cell activation at
rom *INSERM UMR S 872 and †INSERM UMR S 689, Paris, France; and the
Department of Molecular Immunology, Medical University of Vienna, Vienna,
ustria. This work was supported in part by the “Fondation de France” (grant no.
006005656) and the GEN-AU Program of the Austrian Federal Ministry of
ducation, Science, and Culture.m
Manuscript received November 30, 2006; revised manuscript received March 22,
007, accepted April 3, 2007.he blood-vessel interface. Such a regulation might be
fficiently coordinated by leukocytes-platelets-endothelial
ell-cell communication through a common receptor:
D31. This hypothesis is supported by the following
onsiderations: 1) all (and exclusively) cells of the blood-
essel interface express CD31 (2); 2) CD31 functions as
oth a homophilic and heterophilic adhesion receptor (3),
hich facilitates dialog between cells of different origin such
s leukocytes, platelets, and endothelial cells; 3) the CD31
romoter contains 2 consensus sites for nuclear factor-kappa
binding (4), which suggests a function for CD31 in
nflammatory contexts; 4) the phosphorylation of the 2
mmunoreceptor tyrosine-based inhibitory motifs in the
ntracellular domain of CD31 allows the activation of the
ound SHP2 tyrosine phosphatase, which leads to the
nhibition of cell functions mediated by protein tyrosine
inases (5); and 5) homophilic ligation of CD31 mediates
utual repulsion of viable cells by transmitting “detach-
ent” signals (6). Interestingly, up to 50% of circulating T
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July 24, 2007:344–50 CD31/Treg in Atherosclerosisymphocytes in adult human blood lack detectable CD31 at
heir surface (7), and such loss may be a consequence of
heir activation (8–10).
Furthermore, activated endothelial cells and dendritic
ells upon maturation lose CD31 in response to inflamma-
ory stimuli (11,12). We therefore hypothesized that the
athologic interaction between activated leukocytes and
ndothelial cells in atherosclerosis occurs because the
hysiological inhibition driven by CD31-CD31 and/or
D31-heterophylic (13) signaling is lost. Indeed, we have
ecently shown (14) that loss of CD31 at the surface of
irculating T-cells positively correlates with the occurrence
f atherothrombosis in mice and of (atherothrombotic)
bdominal aortic aneurysm in patients (15). The presence of
D31 on T lymphocytes showed immunoregulatory prop-
rties on the effector function of leukocytes over cells of the
ascular wall in vitro (15).
In the present study, we sought to evaluate whether a
ubstitute CD31 signaling could restore the regulation of
he immune response at the blood-vessel interface in an
n vivo experimental model of atherosclerosis.
aterials and Methods
tudy protocol. Female apolipoprotein E knockout mice
rom our breeding facility were maintained on a regular
how diet and kept under standard conditions. All experi-
ents conformed to the “Position of the American Heart
ssociation on Research Animal Use,” adopted on Novem-
er 11, 1984. We expressed our deoxyribonucleic acid
lasmids encoding CD31 receptor globulin (Rg), composed
f the entire extracellular portion of CD31 fused to constant
arts of human immunoglobulin (Ig) G1 (13,16) in vivo in
ice (n  14) by intramuscular gene electrotransfer as
reviously described (17). Control mice received either
D31Rg 1-2 that lacked the two N-terminal Ig domains
f CD31 (n  14) or phosphate-buffered saline (PBS) (n 
4). Briefly, 15 g of plasmid deoxyribonucleic acid was
njected in each tibial cranial muscle, and 8 transcutaneous
lectric pulses (20 ms, 200 V/cm, 2 Hz, ECM 800 electro-
orator, BTX, San Diego, California) were applied through
plate electrodes on both sides of the limb. These were the
ptimal conditions for skeletal muscle gene transfer, as
etermined by Mir et al. (18). Plasmid products were
etected up to 4 weeks by plasma protein electrophoresis
nd immunoblotting for the human IgG1-Fc portion of
D31 fusion proteins (data not shown). Over 6 months, we
epeated the gene transfer every fifth week starting from age
weeks. At the end of the study, the mice were euthanized
nder anesthesia.
lasma and circulating cell analysis. Blood was drawn
rom the right heart ventricle and collected in heparinized
ubes. Plasma was analyzed for protein (Lowry method) and
holesterol (France-méthode “CHOD-PAP,” Boehringer
annheim, Mannheim, Germany) content and for IgGntibodies directed against the human IgG1-Fc of the oonstructs by enzyme-linked im-
unosorbent assay (coating 
olyclonal human IgG, detection
horseradish peroxidase [HRP]-
onjugated rabbit antimouse IgG
ntibodies and reading at 450 to
70 nm). The cell pellet was sub-
ected to density gradient centrifu-
ation over 1-ml Ficoll in a 5-ml
ound-bottom tube. The periph-
ral blood mononuclear cells were
rocessed for flow cytometry anal-
sis. Fluorescent monoclonal anti-
odies (CD3-APC, CD4-PerCP,
D8-PE, CD69-PE-Cy7,
D45-FITC; all from BD Bio-
ciences, San Jose, California)
ere used simultaneously for char-
cterization of lymphocyte population and activation status.
irculating regulatory T cells (Treg) were quantified using a
taining protocol from eBioscience, San Diego, California;
CD4-FITC, CD25-APC, FoxP3-PE antibodies) and a
SRII flow cytometer with the DIVA analysis software (BD
iosciences).
therosclerotic plaque analysis. We measured atheroscle-
otic plaque extent on 4 oil-red O-stained 10-m-thick
ortic root cryosections at fixed distance points from the
eginning of the valve as previously described (19). We also
nalyzed brachiocephalic artery lesion size on 5 cross-
ections cut at 50-m intervals starting from its origin from
he aortic arch. Plaque composition was analyzed by specific
olyacid histologic stains using a customized orcein/
asson’s trichrome (MT) staining protocol.
mmunohistochemistry. The presence of CD31Rg gene
ransfer products was evaluated by immunohistochemistry
n aortic root cryosections using a biotinylated monoclonal
ntibody directed against the Fc portion of human IgG1
13). Staining was revealed by either Vectastain ABC-HRP
nd DAB substrate (Vector, Burlingame, California) and
ight microscopy or by streptavidin-FITC and fluorescence
icroscopy using a Zeiss Axiovert 200M microscope and
xioVision image capture software. Endothelial cells were
tained with FITC-conjugated lectin BSI (Bandeiraea
implicifolia-I). CD31-positive cells were visualized with a
iotinylated monoclonal antibody directed against mouse
D31 (clone MEC 13.3, BD Biosciences) and AlexaFluor
55-conjugated streptavidin. T lymphocytes and macro-
hages in aortic root plaques were assessed by using mono-
lonal antibodies directed against Thy1.2 (Serotec, Oxford,
nited Kingdom) and Mac3 (BD Biosciences), respectively,
nd an AlexaFluor 555-conjugated secondary antibody.
mmunostained slides were cover-mounted with Vecta-
hield HardSet with DAPI (Vector). Plaque-infiltrating
hy1.2- and Mac3-positive cells (red) were counted by
omputer-assisted image analysis and reported as percentage
Abbreviations
and Acronyms
CD31Rg  CD31 receptor
globulin (domain 1-6)
CD31Rg 1-2  truncated
CD31 receptor globulin
lacking domain 1-2
(domain 3-6)
HRP  horseradish
peroxidase
Ig  immunoglobulin
MT  Masson’s trichrome
staining
PBS  phosphate-buffered
saline
Treg(s)  regulatory
T-cell(s)f total cells (blue).
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CD31/Treg in Atherosclerosis July 24, 2007:344–50-cell suppression assay. Treg function was assessed as
reviously described (20). Briefly, CD4 T-cells from cell
uspensions of spleen and peripheral lymph nodes were
nriched by magnetic cell sorting and sequentially incubated
ith a biotin-conjugated CD25 monoclonal antibody (BD
iosciences) and streptavidin microbeads (Miltenyi Biotec,
ergisch Gladbach, Germany). Two consecutive magnetic
Figure 1 Atherosclerotic Lesions Are Reduced by CD31Rg Trea
(Micrographs) Representative micrographs of MT-stained sections (original magnifi
extracellular matrix appears green. Fibrofatty atherosclerotic lesions are present in
the 3 cusps by CD31Rg treatment. Adventitial inflammation was reduced in the CD
formed at 200, 400, 600, and 800 m from the appearance of the first aortic cus
computer-assisted image analysis. The CD31Rg-treated group showed significantly
versus CD31Rg 1-2 and PBS, n  14 mice/group. CD31Rg  CD31 receptor glo
Masson’s trichrome staining; PBS  phosphate-buffered saline.
ntibody Response to Treatmentd Rate of Plaqu Inflammatory Cells
Table 1 Antibody Response to Treatmentand Rate of Plaque Inflammatory Cells
PBS CD31Rg 1-2 CD31Rg
Antihuman Fc IgG (a.u.)* 0.309 0.035 0.417 0.055† 0.516 0.051†
Mac3 (% cells)‡ 29.0 6.9 29.9 6.5 36.8 7.4
Thy1.2 (% cells)‡ 8.3 3.5 1.6 0.8† 0.4 0.2†
ata are expressed as mean SEM, n 14 mice/group. *a.u. arbitrary units. Plasma levels of
ntihuman Fc immunoglobulin G (IgG) antibodies were measured by enzyme-linked immunosor-
ent assay on individual mouse sera (diluted 1:50) and detected by HRP/TMB substrate (450570
m optical density). †p  0.05 versus PBS. ‡Percentage of macrophages (Mac3, red) and T
ymphocytes (Thy1.2, red) among all cells (DAPI, blue nuclear staining) was evaluated by
mmunohistochemistry in consecutive aortic root sections. Five sections at 100-m intervals were
nalyzed for each staining in all mice. Nine random fields delimited by the internal elastic lamina
green autofluorescence) were used for each section at 200x magnification.
CD31Rg  CD31 receptor globulin; CD31Rg 1-2  truncated CD31 receptor globulin lacking
omain 1-2; PBS  phosphate-buffered saline.ell separations using LS columns (Miltenyi Biotec) yielded
90% CD4CD25 cells. The CD25 cells were har-
ested from the flow-through and contained 0.3% of
D4CD25 T-cells. The CD4 CD25 T-cells were
lated alone or in co-culture with Tregs (CD4CD25) at
ratio of 1:1, 2:1, 4:1, or 8:1 in flat-bottomed 96-well
icroplates (0.5  105 cells/well; total volume 200 l/well
n RPMI 1640 supplemented with Glutamax, 10% FCS,
.02 mM 2 beta-mercaptoethanol, and antibiotics). Cells
ere cultured at 37°C for 72 h and pulsed with 1 Ci of
[H]thymidine (Amersham, Piscataway, New Jersey) for the
ast 18 h of culture. Thymidine incorporation was assessed
sing a TopCount NXT scintillation counter (Perkin
lmer, Waltham, Massachusetts).
tatistical analysis. Data are expressed as mean  SEM
nless otherwise indicated in the text. Differences between
roups were analyzed by 1-factor ANOVA and Bonferroni
ost hoc test. For the analysis of atherosclerotic lesion size and
-cell suppression, we used 1-factor ANOVA with repeated
easures and Bonferroni post-hoc test. Differences were con-
idered statistically significant when the p value was 0.05.
t
40x). Myocardiocytes are stained red, elastin fibers and nuclei appear black,
aortic cups in PBS and CD31Rg 1-2 groups, whereas they are limited to 2 of
group (white arrows). (Bottom right panel) Morphometric analysis was per-
rting from the ventricular side of the aortic root, by oil-red O staining and
er lesions as compared to the CD31Rg 1-2 and PBS control groups. *p  0.01
CD31Rg 1-2 truncated CD31 receptor globulin lacking domain 1-2; MT tmen
cation
the 3
31Rg
p, sta
small
bulin;
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July 24, 2007:344–50 CD31/Treg in Atherosclerosisesults
ice groups did not differ for body weight, total cholesterol,
lasma protein levels, and blood cell count (data not shown).
lasma IgG directed against human IgG1-Fc was similarly
ncreased in CD31Rg and CD31Rg 1-2–treated mice as
ompared with PBS control mice (Table 1), suggesting that
he in vivo responses to CD31Rg treatment were not due to
econdary immune effects.
educed atherosclerosis plaque extent and vulnerability
pon CD31Rg treatment. Atherosclerotic lesions at the
evel of the aortic root were significantly smaller in
D31Rg-treated mice as compared the PBS and CD31Rg
1-2 control mice (Fig. 1). Lesion size in the brachioce-
halic artery was not different in the 3 groups, but a very
arge intragroup variability was observed because the site of
esion development is not constant at this location. Median
min-max) plaque size was 172 (138 to 350)  103 m2 in
BS, 213 (113 to 407)  103 m2 in CD31Rg 1-2, and
94 (146 to 262)  103m2 in CD31Rg (p  NS). Plaque
omposition as evaluated on MT staining did not differ
mong the 3 groups at the aortic root level (Fig. 1). At
ariance, analysis of MT-stained brachiocephalic athero-
clerotic plaques of comparable size among the 3 groups
howed that CD31Rg treatment was associated with
lunted neovascularization and intraplaque hemorrhage as
ompared CD31Rg 1-2 and PBS control treatment (Fig.
Figure 2 Reduced Neovascularization and Plaque Hemorrhage U
Masson’s trichrome staining and double immunohistochemistry for CD31 (MEC 13
micrographs showing blunted neovascularization and intraplaque hemorrhage in CD
CD31Rg 1-2 (6 of 14 mice 42%) and PBS (9 of 14 mice, 64%) control mice. Intra
vascularization as detected by FITC-lectin BSI staining of endothelial cells within th
sels were negative for CD31 (red, MEC13.3 column) as showed by the merge of fl
as in Figure 1.). We found that MT staining documented consistent
ntraplaque fibrin (red) deposition in 9 of 14 (PBS) and 6 of
4 (CD31Rg1-2) control mice (p  NS), whereas tiny
brin deposits could be detected in only 3 of 14 CD31Rg-
reated mice (p  0.05 vs. PBS, chi-square test). Fibrin
eposits were topologically distributed in areas of rich
eovascularization, as detected by FITC-lectin BSI staining
f endothelial cells within the plaques (Fig. 2). Of note,
ost of the intraplaque neovessel endothelial cells were
egative for CD31, as shown by the merged red and green
uorescent channels (Fig. 2).
The whole cell density (number of nuclei/m2 tissue) was
ot different in the 3 treatment groups. Specific immuno-
uorescence analysis showed that most of the infiltrating
ells were macrophages (Mac3 cells) and that the rate of
acrophage infiltration was not affected by treatment.
nterestingly, although considerably lower in all groups, the
ercentage of infiltrating T-cells was reduced by 20-fold in
esions of CD31Rg and by 5-fold in the CD31Rg 1-2–
reated mice as compared to PBS control mice (p 0.01 vs.
BS) (Table 1).
D31Rg binds to plaque infiltrating cells. Immunohisto-
hemistry demonstrated that CD31Rg, but not CD31Rg1-2,
ound a portion of the plaque infiltrating cells (Fig. 3),
uggesting that stable binding is dependent on the presence
f the extracellular CD31 domains 1-2 that are lacking in
In Vivo Expression of CD31Rg
d endothelia (lectin BSI) on comparable brachiocephalic plaques. Representative
-treated mice (3 of 14 mice, 21%, p  0.05, chi-square test) as compared to
e fibrin deposition (red, MT column, black arrows) localizes at areas of rich neo-
ues (green, BSI column, white arrows). Of note, most of the intraplaque neoves-
ent images (MERGE  DAPI column). Original magnification 100. Abbreviationspon
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CD31/Treg in Atherosclerosis July 24, 2007:344–50he CD31Rg 1-2 plasmid product. Interestingly, CD31Rg
inding could be detected not only on cells highly express-
ng CD31 (CD31bright cells), but also on cells that had
artially lost their surface CD31 expression (CD31low cells)
Fig. 3). This binding is probably due to binding of CD31
o heterophilic ligands, including cell surface glycosamino-
lycan, alpha-V-beta-3 integrin, CD38, or TCD31L
13,16).
nhanced Treg content in the blood of CD31Rg-treated
nimals. Flow cytometry analysis of peripheral blood
ononuclear cells showed that the percentages of CD3
total), CD4 (helper), and CD8 (cytotoxic) T-cells
ithin the lymphocyte population (light scatter x CD45
ouble gate) were similar in the 3 groups. In contrast, the
ercentage of CD4/CD69 double-positive (activated
-helper) cells among total T lymphocytes was significantly
educed in the blood of CD31Rg-treated mice (Fig. 4).
n vitro proliferation studies showed that T-cell activation
as hampered in the CD31Rg group as compared with the
ontrol group, because splenocyte growth was significantly
educed in response to the mitogen concanavalin A (Fig. 5).
Figure 3 CD31Rg Binds to Plaque-Infiltrating Cells
Immunohistochemistry of CD31Rg in aortic root crysosections. CD31Rg (A),
but not CD31Rg 1-2 (B), binds a consistent number of plaque-infiltrating
cells. CD31Rg binding was detected on CD31bright cells (white arrows) as well
as on CD31low cells (white arrow heads). CD31Rg staining was revealed by
HRP/DAB (brown, A to B; green, C and F), nuclei were counterstained by
hematoxylin (light blue, A to B) or DAPI (blue, E to F). CD31 cells were visu-
alized by a monoclonal rat antimouse CD31 antibody (MEC13.3) and an Alex-
afluor 555-conjugated secondary antibody (red, D and F). Original magnification
200. A  adventitia; L  lumen; M  media; other abbreviations as in Figure 1.n agreement with this finding, the percentage of Tregs was
ignificantly increased in the blood of CD31Rg-treated
ice (9  0.7%) as compared to CD31Rg 1-2 (5  0.8%,
 0.01) or PBS (5  1%, p  0.01) control groups
Fig. 6). Of note, the suppressive function of Treg was not
ltered by the CD31Rg treatment; Tregs derived from
Figure 4 Circulating Activated T Lymphocytes
Are Reduced Upon In Vivo Expression of CD31Rg
The percentage of circulating activated (CD69) helper (CD4) cells within T
lymphocytes (double gate FSC/SSC x CD3) was analyzed by flow cytometry. At
the end of the study, CD31Rg-treated mice showed significantly reduced num-
bers of circulating activated T-helper lymphocytes as compared to PBS and
CD31Rg 1-2 controls. Similar data were obtained 1 week after the first elec-
troporation round. *p  0.05 versus PBS and CD31Rg 1-2, n  14 mice/
group. Abbreviations as in Figure 1.
Figure 5 Reduced T Lymphocyte Response
Upon In Vivo Expression of CD31Rg
Spleen cells were stimulated with concanavalin A for 3 days. 3[H]thymidine was
added to the cultures for the last 18 h. Cell proliferation was measured in a
beta counter and is expressed in counts per minute (cpm). T-cell proliferation
of CD31Rg-treated mice was significantly reduced as compared control mice,
even in response to a powerful stimulus such as the polyclonal mitogen con-
canavalin A. *p  0.05 versus CD31Rg 1-2 and PBS, n  14 mice/group.
Abbreviations as in Figure 1.
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July 24, 2007:344–50 CD31/Treg in AtherosclerosisD31Rg- or PBS-treated animals reduced proliferation of
D4 CD25-negative cells to similar extent (Fig. 6).
iscussion
ecent studies suggest that CD31 (PECAM-1) could
unction as a regulatory molecule in vascular biology and
mmunity because it is expressed exclusively by endothelial
nd blood cells. Homophilic as well as heterophilic CD31
inding was shown to drive inhibitory signals between
pposing cells (13,21) as well as detachment signals, pre-
enting, for instance, phagocyte ingestion of viable cells (6).
n this perspective, the presence of CD31 could serve as a
leave me alone” signal for flowing cells and the cells lining
he vascular wall (21). Interestingly, atherosclerosis and its
cute clinical manifestations are characterized by the acti-
ation of circulating lymphocytes (22,23), and T-cell acti-
Figure 6 In Vivo CD31Rg Expression
Increases Circulating Tregs
(Top) The percentage of CD25/FoxP3 regulatory T cells (Tregs) within total
CD4 T lymphocytes was significantly increased in the peripheral blood of
CD31Rg-treated mice as compared with the controls. *p  0.01, n  14
mice/group. (Bottom) The suppressive capacity of Tregs was not altered by
CD31Rg treatment (n  14 mice/group, NS). CD4CD25 negative T-cells were
incubated with Tregs at the indicated ratios, and proliferation was measured as
before. Other abbreviations as in Figure 1.ation is associated with the loss of CD31 expression (24). iWe have recently reported (14) that the loss of CD31 on
irculating T-cells is associated with enhanced activation of
he immune response toward the vascular wall and the
ccurrence of plaque complications in atherosclerotic mice,
s well as with the incidence of atherosclerotic abdominal
ortic aneurysm in patients (15). In this study, we sought to
valuate the hypothesis that replacing CD31 signaling could
estore the regulation of lymphocyte activation, leading to
eduction of disease extent in experimental atherosclerosis.
herefore, we expressed a soluble form of CD31, CD31Rg,
hich had previously demonstrated regulatory capacities
n vitro (13), in atherosclerosis-prone apoE KO mice by
ntramuscular gene transfer technology.
Repeated CD31Rg treatment over 6 months resulted in a
ignificant reduction of atherosclerotic lesion extent. We
ound that CD31Rg, but not a truncated form lacking the
rst 2 extracellular domains of CD31, bound to plaque-
nfiltrating cells. In parallel, the truncated construct was not
ble to affect disease extent, suggesting that the first 2
omains of the CD31 ectodomain are important for the
eneficial effect. In this respect, previous studies had sug-
ested that individually distinct CD31 extracellular domains
ight mediate distinct function in CD31 signaling (3).
Independently of lesion extent, CD31Rg treatment also
educed the occurrence of fibrin deposits in areas of plaque
eovascularization. The plaque neovessels have been re-
ently indicated as a major mechanism of plaque complication
nd growth both in patients (25,26) and atherosclerosis-prone
ice (27) because of their immature state and consequent
ragility (25). Interestingly, the endothelial cells of plaque
eovessels were frequently negative for CD31 staining, as
eported in a previous study in atherosclerotic patients (28).
ur data suggest that replacement of CD31 signaling could
mprove neovessel stability (29) and protect from in-
raplaque hemorrhage.
The beneficial effects of CD31Rg on atherogenesis were
ccompanied by prevention of T-cells from entering the
eveloping plaque: though in the CD31Rg 1-2–treated
nimals the number of T-cells was reduced (5-fold), virtu-
lly no plaque-infiltrating T-cells could be detected in mice
reated with CD31Rg (20-fold reduction). Furthermore,
D31Rg blunted the T-cell activation, as detected by the
educed expression of activation markers on circulating
-cells, as well as by a lower proliferative response to
olyclonal stimulation. This work is in agreement with our
revious findings that CD31Rg induces in vitro hypore-
ponsiveness of T-helper lymphocytes (13,16). Combining
he latter work with the new finding, we reasoned that
D31Rg might produce T-cell hyporesponsiveness by con-
erting some of its target T-cells into Tregs. Indeed, our
ata show that CD31Rg treatment in vivo results in
ncreased numbers of circulating Tregs. We can also show
hat the suppressive function of circulating Tregs is not
ltered by CD31Rg treatment, implying that their increased
umber might explain the concomitant observed reduction
n circulating activated T-cells in our study.
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CD31/Treg in Atherosclerosis July 24, 2007:344–50In accord with this finding, it was shown that the
berrant T-cell activation observed in patients with acute
oronary syndromes is linked to a lack of T-cell regulation
30) and reduced numbers and function of circulating Tregs
n the acute phases of coronary artery diseases (31). Fur-
hermore, experimental studies have demonstrated that
regs play a crucial role in the control of atherogenesis in
ice (20). Although the molecular mechanisms involved in
he CD31-mediated induction of circulating Treg remain to
e elucidated, the present study indicates that CD31-
argeting therapeutic approaches may be envisaged for
reventing and treating atherosclerotic diseases.
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